Evidence map›Paper›PMID 28349127›Full record

ArticleBioengineering & translational medicine2016

Polymeric nanoparticle-based delivery of TRAIL DNA for cancer-specific killing.

Stephany Y Tzeng, David R Wilson, Sarah K Hansen, Alfredo Quiñones-Hinojosa, Jordan J Green

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineering & translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. Nano-TRAIL: a promising path to cancer therapy.Cancer drug resistance (Alhambra, Calif.) · 2023
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Nanoparticles for Stem Cell Therapy Bioengineering in Glioma.Frontiers in bioengineering and biotechnology · 2020
    Review
  10. Review
  11. Article
  12. Editorial: The launch phase ofBioengineering & translational medicine · 2019
    Article
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Stephany Y TzengDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD; The Institute for Nanobiotechnology and the Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD.
David R WilsonDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD; The Institute for Nanobiotechnology and the Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Sarah K HansenDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD; The Institute for Nanobiotechnology and the Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Alfredo Quiñones-HinojosaDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD.
Jordan J GreenDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD; The Institute for Nanobiotechnology and the Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Material Science and Engineering, Johns Hopkins University, Baltimore, MD.

Funding

Wilmer Core Grant for Vision ResearchP30EY001765 · NEI · JOHNS HOPKINS UNIVERSITY · PI Ji Yi · 1985 to 2026
$22.1M
Gene Delivery Nanoparticles to Treat GlioblastomaR01EB016721 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI GREEN, JORDAN · 2013 to 2017
$1.9M
Cancer-specific nanoparticle-mediated gene therapy to treat hepatocellular carcinomaR01EB022148 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI GREEN, JORDAN · 2016 to 2019
$1.5M
NEI NIH HHS P30 EY001765NIBIB NIH HHS R01 EB016721NIBIB NIH HHS R01 EB022148
6 · The paper itself

Abstract

Lack of specificity in cancer therapeutics severely limits the efficacy of many existing treatment modalities. The use of Tumor Necrosis Factor-related Apoptosis-Inducing Ligand (TRAIL) is of interest to the field due to this protein's ability to cause cell death specifically in cancer cells without harming the surrounding healthy tissue. Here, we report that polymeric nanoparticles, based on synthetic poly(beta-amino ester)s (PBAEs) and containing DNA, are able to selectively transfect cancer cells

Indexed as

nanoparticlesnon-viral gene therapypoly(beta-amino ester)polymerTRAIL

Identifiers

PMID28349127
PMCPMC5365091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.